The presence of tumor infiltrating lymphocytes (TILs), especially CD8+ T-cells, has been recognized as a marker of anti-tumor immune response across a wide range of cancers, [5, 24–27] and a positive correlation has been linked to high TIL counts at pre-treatment samples and good prognosis [28, 52, 53]. The gene discussed is CD8A; the disease is neoplasm.